Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1811 results
September 2015
-
Media Release
Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET
In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional… -
Media Release
Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval
Positive opinion from EU review body puts Entresto on track to be approved for HFrEF patients across Europe likely by year end Entresto was studied in world's largest heart failure trial which… -
Media Release
Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires
New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E.… -
Media Release
Novartis nomme le Dr James E. Bradner Président des Instituts Novartis pour la Recherche Biomédicale suite au prochain départ à la retraite de Mark Fishman
Un nouveau responsable pour continuer de stimuler l'innovation à long terme au sein de la recherche chez Novartis dans des domaines thérapeutiques très variés Bâle, le 24 septembre 2015 -… -
Media Release
Novartis ernennt Dr. James E. Bradner zum Präsidenten der Novartis Institutes for BioMedical Research, da Mark Fishman in den Ruhestand tritt
Neuer Leiter wird weiterhin langfristige Innovationen in zahlreichen Therapiegebieten der Novartis Forschung vorantreiben Basel, 24. September 2015 - Novartis gab heute bekannt, dass… -
Media Release
Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and… -
Media Release
Novartis lance « Novartis Access », une gamme de médicaments à prix abordables pour lutter contre les maladies chroniques dans les pays à faible revenu
Une approche unique en son genre dans l'industrie de la santé, qui vise à rendre 15 médicaments plus facilement disponibles et plus accessibles pour traiter les maladies cardiovasculaires, le diabète… -
Media Release
Novartis lanciert "Novartis Access", ein Portfolio von erschwinglichen Medikamenten zur Behandlung von chronischen Erkrankungen in Ländern mit niedrigen Einkommen
Neuartiger Portfolioansatz in der Gesundheitsbranche mit dem Ziel, die Verfügbarkeit und Erschwinglichkeit von 15 Medikamenten gegen Herz-Kreislauf-Erkrankungen, Diabetes, Atemwegserkrankungen und… -
Story From Our Labs
Stopping free radicals at their source
Compounds that block the production of damaging molecules might shed light on their role in disease—and lead to new therapies.
-
Story Access to Healthcare
Confronting the global spread of chronic disease
Chronic diseases like cancer and diabetes were once the preserve of wealthy countries but are now increasingly common in lower-income countries too as populations age and lifestyles change.
-
Media Release
Swissmedic approves Novartis' new heart failure medicine Entresto(TM)
Decision by Swiss Health Authority follows US Food and Drug Administration (FDA) approval of Entresto in July, serves as an important reference approval for multiple other health authorities… -
Story Access to Healthcare
Malaria fighter rides bicycle into battle with disease
Healthcare worker Dismus Mwalukwanda is on the front line of the battle against malaria. Saving lives is his priority.